Skip to main content
SpringerLink
Log in

The Role of Metformin in Metformin-Associated Lactic Acidosis (MALA): Case Series and Formulation of a Model of Pathogenesis

Drug Safety volume 36, pages 733–746 (2013)Cite this article

Abstract

Background

Lactic acidosis is an adverse event associated with metformin usage. Patients with metformin-associated lactic acidosis (MALA), however, often have other conditions contributing to the event. The relative contribution of metformin is often unclear. MALA is usually diagnosed without measuring the plasma concentrations of metformin.

Objectives

The objectives of this study were, first, to examine the plasma concentrations of metformin, lactate and creatinine and the arterial pH of patients with suspected MALA and, second, to review critically the mechanisms of MALA.

Methods

Patients who were suspected of having MALA were identified during the period October 2008–September 2011. Repeated blood samples were collected to determine the plasma concentrations of lactate, metformin and creatinine. The pH of arterial blood was also measured on several occasions in each patient.

Results

Patients (n = 15; 9 female, 6 male) were 70 ± 12 years of age. There was one acute metformin overdose (estimated dose 5 g). Metformin was undetectable in one patient and one patient had therapeutic concentrations of metformin on admission (<5 mg/L). There were ten patients with chronic kidney disease, whereby the estimated glomerular filtration rate (eGFR) was less than 60 mL/min/1.73 m2 before the acidotic event. Metformin doses ranged from 1 to 3 g daily (excluding the deliberate overdose). On admission, the mean plasma concentration of metformin on admission was 29.8 ± 19.1 mg/L (mean ± SD), the mean lactate concentration was 12.9 ± 6.1 mmol/L and the mean pH was 7 ± 0.2. The mean creatinine concentration on admission was 481 ± 225 μmol/L. The main pre-admission symptoms were vomiting and diarrhoea (n = 12). There were linear relationships between venous lactate, venous creatinine and arterial pH, with the venous plasma concentrations of metformin in most patients. Three patients died but metformin was unlikely to have been a significant factor.

Discussion and review

Most patients with MALA presented to the hospital with high metformin concentrations. The following factors appear to have been involved in the development of MALA in these patients: vomiting and diarrhoea, acute kidney injury, high doses or excessive accumulation of metformin, and acute disease states leading to tissue hypoxia. The extent of metformin accumulation in patients with MALA can be determined by investigating the concentrations of metformin. We suggest that the development of MALA is due to a positive feedback system involving one or more of these factors. While nausea is a common adverse effect of metformin, vomiting and diarrhoea out of the ordinary is a clear first sign of MALA. In this condition, dosage with metformin should be stopped and patients should receive urgent medical attention.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3

References

  1. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203.

    Article  PubMed  CAS  Google Scholar 

  2. Runge S, Mayerle J, Warnke C, et al. Metformin-associated lactic acidosis in patients with renal impairment solely due to drug accumulation? Diabetes Obes Metab. 2008;10(1):91–3.

    PubMed  CAS  Google Scholar 

  3. Luft D, Deichsel G, Schmulling RM, et al. Definition of clinically relevant lactic acidosis in patients with internal diseases. Am J Clin Pathol. 1983;80(4):484–9.

    PubMed  CAS  Google Scholar 

  4. Holstein A, Stumvoll M. Contraindications can damage your health–is metformin a case in point? Diabetologia. 2005;48(12):2454–9.

    Article  PubMed  CAS  Google Scholar 

  5. Misbin RI. The phantom of lactic acidosis due to metformin in patients with diabetes. Diabetes Care. 2004;27(7):1791–3.

    Article  PubMed  Google Scholar 

  6. Stades AM, Heikens JT, Erkelens DW, et al. Metformin and lactic acidosis: cause or coincidence? A review of case reports. J Intern Med. 2004;255(2):179–87.

    Article  PubMed  CAS  Google Scholar 

  7. Lalau JD, Race JM. Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations. Drug Saf. 1999;20(4):377–84.

    Article  PubMed  CAS  Google Scholar 

  8. van Berlo-van de Laar IR, Vermeij CG, Doorenbos CJ. Metformin associated lactic acidosis: incidence and clinical correlation with metformin serum concentration measurements. J Clin Pharm Ther. 2011;36(3):376–82.

    Article  PubMed  CAS  Google Scholar 

  9. Lalau JD, Mourlhon C, Bergeret A, et al. Consequences of metformin intoxication. Diabetes Care. 1998;21(11):2036–7.

    Article  PubMed  CAS  Google Scholar 

  10. Lalau JD, Lacroix C, Compagnon P, et al. Role of metformin accumulation in metformin-associated lactic acidosis. Diabetes Care. 1995;18(6):779–84.

    Article  PubMed  CAS  Google Scholar 

  11. Seidowsky A, Nseir S, Houdret N, et al. Metformin-associated lactic acidosis: a prognostic and therapeutic study. Crit Care Med. 2009;37(7):2191–6.

    Article  PubMed  CAS  Google Scholar 

  12. Bruijstens LA, van Luin M, Buscher-Jungerhans PM, et al. Reality of severe metformin-induced lactic acidosis in the absence of chronic renal impairment. Neth J Med. 2008;66(5):185–90.

    PubMed  CAS  Google Scholar 

  13. Lalau JD, Lemaire-Hurtel AS, Lacroix C. Establishment of a database of metformin plasma concentrations and erythrocyte levels in normal and emergency situations. Clin Drug Investig. 2011;31(6):435–8.

    Article  PubMed  CAS  Google Scholar 

  14. Zarghi A, Foroutan SM, Shafaati A, et al. Rapid determination of metformin in human plasma using ion-pair HPLC. J Pharm Biomed Anal. 2003;31(1):197–200.

    Article  PubMed  CAS  Google Scholar 

  15. Chang LC, Hung SC, Yang CS. The case. A suicidal woman with delayed high anion gap metabolic acidosis. Kidney Int. 2009;75(7):757–8.

    Article  PubMed  Google Scholar 

  16. Gjedde S, Christiansen A, Pedersen SB, et al. Survival following a metformin overdose of 63 g: a case report. Pharmacol Toxicol. 2003;93(2):98–9.

    Article  PubMed  CAS  Google Scholar 

  17. Wills BK, Bryant SM, Buckley P, et al. Can acute overdose of metformin lead to lactic acidosis? Am J Emerg Med. 2010;28(8):857–61.

    Article  PubMed  Google Scholar 

  18. Nisse P, Mathieu-Nolf M, Deveaux M, et al. A fatal case of metformin poisoning. J Toxicol Clin Toxicol. 2003;41(7):1035–6.

    Article  PubMed  Google Scholar 

  19. Dell’Aglio DM, Perino LJ, Kazzi Z, et al. Acute metformin overdose: examining serum pH, lactate level, and metformin concentrations in survivors versus nonsurvivors: a systematic review of the literature. Ann Emerg Med. 2009;54(6):818–23.

    Article  PubMed  Google Scholar 

  20. Wang DS, Kusuhara H, Kato Y, et al. Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol Pharmacol. 2003;63(4):844–8.

    Article  PubMed  CAS  Google Scholar 

  21. Protti A, Fortunato F, Monti M, et al. Metformin overdose, but not lactic acidosis per se, inhibits oxygen consumption in pigs. Crit Care. 2012;16(3):R75.

    Article  PubMed  Google Scholar 

  22. Shenoy C. Metformin-associated lactic acidosis precipitated by acute renal failure. Am J Med Sci. 2006;331(1):55–7.

    Article  PubMed  Google Scholar 

  23. van Sloten TT, Pijpers E, Stehouwer CD, et al. Metformin-associated lactic acidosis in a patient with normal kidney function. Diabetes Res Clin Pract. 2012;96:e57–8.

    Article  PubMed  Google Scholar 

  24. Brassoe R, Elkmann T, Hempel M, et al. Fulminant lactic acidosis in two patients with Type 2 diabetes treated with metformin. Diabet Med. 2005;22(10):1451–3.

    Article  PubMed  CAS  Google Scholar 

  25. Almirall J, Briculle M, Gonzalez-Clemente JM. Metformin-associated lactic acidosis in type 2 diabetes mellitus: incidence and presentation in common clinical practice. Nephrol Dial Transplant. 2008;23(7):2436–8.

    Article  PubMed  CAS  Google Scholar 

  26. Lacher M, Hermanns-Clausen M, Haeffner K, et al. Severe metformin intoxication with lactic acidosis in an adolescent. Eur J Pediatr. 2005;164(6):362–5.

    Article  PubMed  Google Scholar 

  27. Brady WJ, Carter CT. Metformin overdose. Am J Emerg Med. 1997;15(1):107–8.

    Article  PubMed  CAS  Google Scholar 

  28. Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50(2):81–98.

    Article  PubMed  CAS  Google Scholar 

  29. Fitzgerald E, Mathieu S, Ball A. Metformin associated lactic acidosis. BMJ. 2009;339:b3660.

    Article  PubMed  Google Scholar 

  30. Clausen SW. Anhydremic acidosis due to lactic acid. Am J Dis Child. 1925;29(6):761–6.

    CAS  Google Scholar 

  31. Assan R, Heuclin C, Ganeval D, et al. Metformin-induced lactic acidosis in the presence of acute renal failure. Diabetologia. 1977;13(3):211–7.

    Article  PubMed  CAS  Google Scholar 

  32. Guo PY, Storsley LJ, Finkle SN. Severe lactic acidosis treated with prolonged hemodialysis: recovery after massive overdoses of metformin. Semin Dial. 2006;19(1):80–3.

    Article  PubMed  Google Scholar 

  33. Roberts F, Ryan GJ. The safety of metformin in heart failure. Ann Pharmacother. 2007;41(4):642–6.

    Article  PubMed  CAS  Google Scholar 

  34. Tahrani AA, Varughese GI, Scarpello JH, et al. Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated? BMJ. 2007;335(7618):508–12.

    Article  PubMed  CAS  Google Scholar 

  35. Johnson JA, Simpson SH, Toth EL, et al. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes. Diabet Med. 2005;22(4):497–502.

    Article  PubMed  CAS  Google Scholar 

  36. Evans JM, Ogston SA, Emslie-Smith A, et al. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia. 2006;49(5):930–6.

    Article  PubMed  CAS  Google Scholar 

  37. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427–43.

    Article  PubMed  CAS  Google Scholar 

  38. Eurich DT, Majumdar SR, McAlister FA, et al. Changes in labelling for metformin use in patients with type 2 diabetes and heart failure: documented safety outweighs theoretical risks. Open Med. 2011;5(1):e33–4.

    PubMed  Google Scholar 

  39. National Collaborating Centre for Chronic Conditions. Type 2 diabetes: national clinical guideline for management in primary and secondary care (update). London: Royal College of Physicians; 2008.

    Google Scholar 

  40. Tucker GT, Casey C, Phillips PJ, et al. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol. 1981;12(2):235–46.

    PubMed  CAS  Google Scholar 

  41. MIMS Online. Diabex. http://www.mimsonline.com.au/ (Accessed 29 Aug 2012).

  42. Rossi S. Australian Medicines Handbook 2011. Adelaide: Australian Medicines Handbook Pty Ltd; 2011.

    Google Scholar 

  43. US Food and Drug Administration (FDA). Metformin hydrochloride tablets. http://www.fda.gov/ohrms/dockets/dailys/02/May02/053102/800471e6.pdf (Accessed 29 August 2012).

  44. Frid A, Sterner GN, Londahl M, et al. Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function: clinical recommendations. Diabetes Care. 2010;33(6):1291–3.

    Article  PubMed  CAS  Google Scholar 

  45. Duong JK, Roberts DM, Furlong TJ, et al. Metformin therapy in patients with chronic kidney disease. Diabetes Obes Metab. 2012;14(10):963–5.

    Article  PubMed  CAS  Google Scholar 

  46. Nye HJ, Herrington WG. Metformin: the safest hypoglycaemic agent in chronic kidney disease? Nephron Clin Pract. 2011;118(4):c380–3.

    Article  PubMed  CAS  Google Scholar 

  47. Rocha A, Almeida M, Santos J, et al. Metformin in patients with chronic kidney disease: strengths and weaknesses. J Nephrol. 2013;26:55–60.

    Article  PubMed  Google Scholar 

  48. McCartney MM, Gilbert FJ, Murchison LE, et al. Metformin and contrast media—a dangerous combination? Clin Radiol. 1999;54(1):29–33.

    Article  PubMed  CAS  Google Scholar 

  49. Goergen SK, Rumbold G, Compton G, et al. Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrast medium for patients receiving metformin. Radiology. 2010;254(1):261–9.

    Article  PubMed  Google Scholar 

  50. Stacul F, van der Molen AJ, Reimer P, et al. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol. 2011;21(12):2527–41.

    Article  PubMed  Google Scholar 

  51. Urakami Y, Okuda M, Masuda S, et al. Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J Pharmacol Exp Ther. 1998;287(2):800–5.

    PubMed  CAS  Google Scholar 

  52. Xia L, Engel K, Zhou M, et al. Membrane localization and pH-dependent transport of a newly cloned organic cation transporter (PMAT) in kidney cells. Am J Physiol Renal Physiol. 2007;292(2):F682–90.

    Article  PubMed  CAS  Google Scholar 

  53. Terada T, Masuda S, Asaka J, et al. Molecular cloning, functional characterization and tissue distribution of rat H+/organic cation antiporter MATE1. Pharm Res. 2006;23(8):1696–701.

    Article  PubMed  CAS  Google Scholar 

  54. Terada T, Inui K. Physiological and pharmacokinetic roles of H+/organic cation antiporters (MATE/SLC47A). Biochem Pharmacol. 2008;75(9):1689–96.

    Article  PubMed  CAS  Google Scholar 

  55. Urakami Y, Kimura N, Okuda M, et al. Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney. Pharm Res. 2004;21(6):976–81.

    Article  PubMed  CAS  Google Scholar 

  56. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000;348(Pt 3):607–14.

    Article  PubMed  CAS  Google Scholar 

  57. Arenas-Pinto A, Grant AD, Edwards S, et al. Lactic acidosis in HIV infected patients: a systematic review of published cases. Sex Transm Infect. 2003;79(4):340–3.

    Article  PubMed  CAS  Google Scholar 

  58. Lee LM, Henderson DK. Tolerability of postexposure antiretroviral prophylaxis for occupational exposures to HIV. Drug Saf. 2001;24(8):587–97.

    Article  PubMed  CAS  Google Scholar 

  59. Megarbane B, Brivet F, Guerin JM, et al. Lactic acidosis and multi-organ failure secondary to anti-retroviral therapy in HIV-infected patients. Presse Med. 1999;28(40):2257–64.

    PubMed  CAS  Google Scholar 

  60. ter Hofstede HJ, de Marie S, Foudraine NA, et al. Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases. Int J STD AIDS. 2000;11(9):611–6.

    Article  PubMed  Google Scholar 

  61. Bodmer M, Meier C, Krahenbuhl S, et al. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care. 2008;31(11):2086–91.

    Article  PubMed  CAS  Google Scholar 

  62. Salpeter SR, Greyber E, Pasternak GA, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;(1):CD002967.

  63. Wiholm BE, Myrhed M. Metformin-associated lactic acidosis in Sweden 1977–1991. Eur J Clin Pharmacol. 1993;44(6):589–91.

    Article  PubMed  CAS  Google Scholar 

  64. Emslie-Smith AM, Boyle DI, Evans JM, et al. Contraindications to metformin therapy in patients with Type 2 diabetes—a population-based study of adherence to prescribing guidelines. Diabet Med. 2001;18(6):483–8.

    Article  PubMed  CAS  Google Scholar 

  65. Nyirenda MJ, Sandeep T, Grant I, et al. Severe acidosis in patients taking metformin—rapid reversal and survival despite high APACHE score. Diabet Med. 2006;23(4):432–5.

    Article  PubMed  CAS  Google Scholar 

  66. Kamber N, Davis WA, Bruce DG, et al. Metformin and lactic acidosis in an Australian community setting: the Fremantle Diabetes Study. Med J Aust. 2008;188(8):446–9.

    PubMed  Google Scholar 

  67. El-Hennawy AS, Jacob S, Mahmood AK. Metformin-associated lactic acidosis precipitated by diarrhea. Am J Ther. 2007;14(4):403–5.

    Article  PubMed  Google Scholar 

  68. van Velzen A, van Riel A, de Vries I, et al. The dangers of metformin: fatal lactic acidosis with therapeutic use due to renal failure. Toxicol Lett. 2008;180:S142–3.

    Article  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Dr. Hari Nandakoban, Dr. Meg J. Jardine and Dr. Mary-Ann Kulh for contributing cases to this case series. Funding for this study was provided by the NH&MRC Program Grant 568612 and the Australian Research Council Grant LP 0990670.

Conflicts of interest

All authors have no conflicts of interest to declare that are directly relevant to the content of this study.

Author information

Authors and Affiliations

  1. School of Medical Sciences, University of New South Wales, Kensington, NSW, Australia

    Janna K. Duong, Garry G. Graham, Kenneth M. Williams & Richard O. Day

  2. Department of Clinical Pharmacology and Toxicology, Level 2 Xavier Building, St Vincent’s Hospital, 390 Victoria Street, Darlinghurst, NSW, 2010, Australia

    Janna K. Duong, Darren M. Roberts, Garry G. Graham, Kenneth M. Williams & Richard O. Day

  3. Department of Nephrology, St. Vincent’s Hospital, Darlinghurst, NSW, Australia

    Timothy J. Furlong & Darren M. Roberts

  4. Department of Renal Medicine, Concord Repatriation General Hospital, Concord, NSW, Australia

    Darren M. Roberts

  5. Department of Endocrinology, St Vincent’s Hospital, Darlinghurst, NSW, Australia

    Jerry R. Greenfield

  6. Diabetes and Obesity Research Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia

    Jerry R. Greenfield

  7. St Vincent’s Hospital Clinical School, Medicine, University of New South Wales, Darlinghurst, NSW, Australia

    Richard O. Day

Authors
  1. Janna K. Duong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Timothy J. Furlong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Darren M. Roberts
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Garry G. Graham
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jerry R. Greenfield
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kenneth M. Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Richard O. Day
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard O. Day.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 2040 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Duong, J.K., Furlong, T.J., Roberts, D.M. et al. The Role of Metformin in Metformin-Associated Lactic Acidosis (MALA): Case Series and Formulation of a Model of Pathogenesis. Drug Saf 36, 733–746 (2013). https://doi.org/10.1007/s40264-013-0038-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40264-013-0038-6

Keywords

search

Navigation